- Home
- DAVE vs BCRX Comparison
DAVE vs BCRX Comparison
Compare DAVE & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVE | BCRX |
|---|---|---|
| Founded | 2017 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | DAVE | BCRX |
|---|---|---|
| Price | $206.48 | $9.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $313.86 | $20.82 |
| AVG Volume (30 Days) | 584.3K | ★ 5.7M |
| Earning Date | 03-02-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | N/A | ★ 1.21 |
| Revenue | N/A | ★ $25,186,000.00 |
| Revenue This Year | $26.28 | N/A |
| Revenue Next Year | $17.38 | $12.55 |
| P/E Ratio | $17.85 | ★ $8.02 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $65.46 | $6.00 |
| 52 Week High | $286.45 | $11.31 |
Technical Indicators
Market Signals| Indicator | DAVE | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.33 | 70.01 |
| Support Level | $182.68 | $7.99 |
| Resistance Level | $222.44 | N/A |
| Average True Range (ATR) | 11.26 | 0.48 |
| MACD | -0.94 | 0.07 |
| Stochastic Oscillator | 28.76 | 68.43 |
Price Performance
Historical ComparisonAbout DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.